JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
| Ticker |
Sentiment |
Impact |
|
ARGX
|
Somewhat Bullish
|
14 %
|
|
BVS
|
Somewhat Bullish
|
41 %
|
|
FULC
|
Somewhat Bullish
|
35 %
|
|
JNJ
|
Neutral
|
28 %
|
